There’s a boatload of interesting stuff recently, including article of interest on the pharmaceutical business, new advances in research, and updates on medical devices:
Yet another article on the growing rejection of pharma reps in offices (from Business Week).
Pfizer lawyer has questions about off-label promotion of drugs – the longstanding debate continues to rage on.
The huge market in diabetes treatment – big and getting bigger!
And, late-breaking news/rumor – Sanofi-Aventis and BMS talking merger?
Yet more cuts at Pfizer – the pain continues.
Fallout from the Pfizer cuts – yes or no? Dan Vasella of Novartis says, not necessarily…
Or, perhaps you think pharma is heading into a black hole…
Can pharma companies continue to succeed as massive, vertically integrated companies? Some thoughts from The Economist.
Abbott handing off diagnostics business to GE Medical.
AstraZeneca and Merck collaborating on biomarkers for heart disease.
Vaccine on Vaccine in the ring – a head-to-head test for Merck and GSK.
Tyco spins off drug unit – welcome to Covidien.
Red wine. Resveratrol. The fountain of youth. One biotech aims to find out.
Some encouraging early stage oncology results for AstraZeneca.
Another potential advance in oncology treatment, involving small molecules and big words.
EPO and cancer – a downbeat report for Amgen.
Coating medical devices with antibiotics – very intriguing concept.